Takeda Announces Its Certification in Select Group of Global Top Employers® 2018
February 20, 2018 17:30 KST
OSAKA, JAPAN--(Business Wire / Korea Newswire) February 20, 2018 -- Takeda Pharmaceutical Company Limited (TOKYO: 4502), (“Takeda”) today announced it has become part of a select group of only thirteen (13) companies and one of two pharmaceuticals to receive global Top Employer® status for 2018. Established over 25 years ago, award certification is given annually by the Top Employers Institute to companies with exceptional employee offerings. The program is organized and designed by the Institute to recognize those that create optimal conditions for their employees to develop professionally and personally, and that achieve the highest standards of excellence for their people.
To be certified globally at least 20 countries, four regions and the applicant company’s global headquarters all needed to be certified by the Top Employer Institute, which Takeda has achieved this year.
“We’d like to thank the Top Employers Institute for recognizing Takeda for the corporate culture we have created,” commented David Osborne, Takeda’s Global Human Resources Officer. “Our focus on patients, combined with our values to act with Integrity, Fairness, Honesty and Perseverance, create a dynamic environment that our people feel strongly about and in which they are empowered to shine.”
The Top Employers Institute assesses company offerings to their employees. It covers 600 HR practices across the following areas:
· Talent Strategy
· Workforce Planning
· Learning & Development
· Performance Management
· Leadership Development
· Career & Succession Management
· Compensation & Benefits
“Takeda really stands out as a global Top Employer for its commitment to people development,” said David Plink, CEO of the Top Employers Institute. “The learning opportunities provided, which enhance the employee journey and are centered on enabling employees to reach their personal professional goals, are first-class and a real differentiator.”
Takeda met the tough requirements of the Top Employers Institute, receiving accreditation in more than 20 countries and regions, across four geographic areas, namely:
· Asia Pacific: Australia, China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand
· Europe: Ireland, Russia, Spain, Turkey and Ukraine
· Latin America: Argentina, Brazil, Colombia, Ecuador, Mexico, Peru and Venezuela
· North America: Canada and United States
· South Africa
“At Takeda, we are passionate about providing the right environment so our people can learn and progress their careers,” said David Osborne. “We endeavor to provide diverse learning opportunities across more than 70 countries through programs at institutions such as Oxford University, Massachusetts Institute of Technology (MIT), Wharton and INSEAD, as well as by establishing mentoring relationships with our most senior leaders.”
To learn more about the Top Employers Institute and the Top Employers certification visit http://www.top-employers.com.
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas, plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit https://www.takeda.com/newsroom/.
Takeda’s Values & People
Takeda is building a patient-centric and customer-centric organization based on Our Values; always act upon Takeda-ism (Integrity, Fairness, Honesty and Perseverance) and do everything in the order of the four priorities of Patient-Trust-Reputation-Business. We put the patients first and foremost, and through that, we build trust with society, which solidifies our reputation, and that finally can lead to our business performance. These are deeply ingrained in our ways of working. They ensure our commitment to quality and that we do the right thing - at all times.
Our local organizations and people are empowered to respond in the best way to customer needs, and have the possibility to develop and thrive in a diverse and agile organization.
Takeda leaders demonstrate strategic thinking, find innovative ways to serve patients, build trust with society, reinforce our reputation, and grow the business. They create an environment that inspires and enables people to collaborate and move the organization forward. They focus on our few designated priorities and deliver superior results. And they elevate the capabilities of our organization now and for the future.
Takeda: Empowering Our People to Shine
Working at Takeda, it is important that our people feel empowered to perform to the very best of their ability as they work towards creating a brighter future for millions of patients worldwide. We enable all our people to grow, providing support and training where needed, and fostering a culture of trust to allow leadership at all levels.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005439/en/
- Takeda Reports First Quarter FY2018 Results
- Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve
- New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
- Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant
- Takeda Receives Clearance from the United States Federal Trade Commission for the Proposed Acquisition of Shire plc